Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting

City Therapeutics (Nasdaq: CTY) will present Phase 1 CITY-FXI data at the ASH Annual Meeting on December 12, 2026.

Rhea-AI Summary

City Therapeutics (Nasdaq: CTY) will present Phase 1 CITY-FXI data at the ASH Annual Meeting on December 12, 2026. The oral presentation will cover an ongoing trial of the RNA interference candidate targeting Factor XI for thromboembolic diseases. It will include results from healthy volunteers receiving single ascending doses and initial data from the first such cohort of adults with Factor V Leiden or the prothrombin G20210A mutation.

A separate poster on December 12 will present preclinical CITY-TFR2 data supporting development for anemia of chronic disease. CITY-TFR2 targets transferrin receptor 2. The meeting runs December 12–15 in New Orleans, Louisiana, and the abstracts are available on the ASH conference website.

Argus Nov 4 session 36 alerts

-14.04% close to close 1.0x rel. volume Open Argus

Details

Market move: CTY -14.04% in the Nov 4 session. Phase 1 data presentation

-11.1% Trough in 6 hr

$922.34M Mkt Cap at Peak Alert

On Nov 4, the day this news came out, CTY closed 14.04% below the previous close. Argus tracked a trough of -11.1% from its starting point during tracking. Our momentum scanner recorded 36 alerts for this stock that day.

Data tracked by StockTitan Argus for the Nov 4 session.

Key Terms

rna interference, factor xi, single-ascending dose, sirna

4 terms

rna interference medical

"developing the next generation of RNA interference (RNAi) therapeutics"

RNA interference is a natural cellular process that acts like a mute switch to reduce or silence the activity of a specific gene by targeting its messenger RNA, the blueprint used to make a protein. For investors, it matters because therapies and diagnostics that harness this mechanism can precisely block disease-causing proteins, creating new drug classes with high potential reward but also scientific, manufacturing and regulatory risks that affect company value.

factor xi medical

"targeting Factor XI (FXI) for thromboembolic diseases"

A plasma protein involved in blood coagulation produced mainly by the liver; Factor XI circulates as an inactive precursor (zymogen) and is converted to its active form, Factor XIa, during the intrinsic coagulation pathway. Its activation amplifies generation of thrombin and stabilizes clots; low levels or malfunction cause a bleeding tendency (Factor XI deficiency), while excessive activity is linked to increased risk of thrombosis.

single-ascending dose medical

"the single-ascending dose (SAD) cohorts of healthy volunteers"

A single-ascending dose (SAD) study is an early-stage clinical test where small groups of volunteers each receive one single dose of a drug, with each subsequent group getting a higher dose if the previous dose is safe. Think of it like stepping up a staircase one step at a time to check stability; investors watch SAD results because they reveal initial safety, how the body handles the drug, and the safe dose range, all of which affect development risk and timelines.

sirna medical

"siRNA targeting hepatic TFR2 as a disease-tailored approach"

Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Preclinical data supporting CITY-TFR2 for anemia of chronic disease to be presented in a poster session

CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced that data from its CITY-FXI and CITY-TFR2 programs will be presented at the 68th American Society of Hematology (ASH) Annual Meeting, taking place December 12–15, 2026, in New Orleans, Louisiana.

An oral presentation will highlight data from the ongoing Phase 1 clinical trial of CITY-FXI, an RNAi therapeutic candidate targeting Factor XI (FXI) for thromboembolic diseases. These data will include results from the single-ascending dose (SAD) cohorts of healthy volunteers (Part A) and the initial data from the first SAD cohort of adults with Factor V Leiden or the prothrombin G20210A mutation (Part B). A poster presentation will highlight preclinical data supporting the clinical development of CITY-TFR2, an RNAi therapeutic candidate targeting transferrin receptor 2 (TFR2) for the treatment of anemia of chronic disease.

Details of the Oral Presentation:

Title: CITY-FXI, a small interfering RNA targeting Factor XI, for treatment of thrombosis disorders: A phase 1 study in healthy adults and adults with Factor V Leiden or prothrombin G20210A mutation
Session Name: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: New Frontiers in Thrombosis: FXI Inhibition, Intervention, and Long-term Outcomes
Session Date: December 12, 2026
Session Time: 2:00–3:30 p.m. CT
Presentation Time: 2:30–2:45 p.m. CT
Location: Ernest N. Morial Convention Center, Room 217–219
Presenting Author: Baisong Mei, M.D., Ph.D., City Therapeutics
Abstract Number: 189

Details of the Poster Presentation:

Title: siRNA targeting hepatic TFR2 as a disease-tailored approach for treating anemia of chronic disease
Session Name: 102. Iron Homeostasis and Biology in Physiological and Pathological Conditions: Poster I
Session Date: December 12, 2026
Session Time: 5:30–7:30 p.m. CT
Location: Ernest N. Morial Convention Center, Hall F
Presenting Author: Kenneth Kelly, M.S., City Therapeutics
Abstract Number: 1122

The abstracts are now available on the ASH conference website at https://www.hematology.org/meetings/annual-meeting.

About City Therapeutics

City Therapeutics is a clinical-stage biotechnology company engineering the next generation of RNA interference (RNAi) therapeutics, with the aim of delivering meaningful and durable benefits for patients in need. City’s lead development programs are CITY-FXI for thromboembolic diseases, CITY-RBP4 for Stargardt disease and other retinal diseases, and CITY-TFR2 for anemia associated with chronic diseases. The City Platform is the engine behind every therapeutic the company develops and integrates deep expertise in trigger engineering, including proprietary cityRNA triggers designed to address limitations of conventional RNAi approaches, tissue-selective delivery, and genetics-driven target selection. For more information, visit www.citytx.com and follow us on LinkedIn, X, and Bluesky.

Contacts:

Media Contact:
Katie Engleman, 1AB
katie@1abmedia.com

Investor Contact:
Stephanie Ascher, Precision AQ
stephanie.ascher@precisionaq.com